Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab

Magnetic Resonance in Medicine

Volumn 67, Issue 1, 2012, Pages 237-245

  Ellingson, Benjamin M ^a   Cloughesy, Timothy F ^a   Lai, Albert ^a   Nghiemphu, Phioanh L ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bevacizumab; diffusion MRI; fDM; functional diffusion map; glioblastoma

Indexed keywords

FREQUENCY DIVISION MULTIPLEXING; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT; SURFACE DIFFUSION; TUMORS;

APPARENT DIFFUSION COEFFICIENT; BEVACIZUMAB; DIFFUSION MAPS; DIFFUSION MRIS; DIFFUSION WEIGHTED IMAGES; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS;

IMAGE ENHANCEMENT;

BEVACIZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; GEOMETRY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NONLINEAR SYSTEM; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

EID: 84355162260     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.23003     Document Type: Article

References (30)

1. CBTRUS. Primary brain tumors in the United States 2004-2006. Chicago, IL: Central Brain Tumor Registry of the United States; 2010.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Morosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO,. Radiotherapy plus concomitant and adjuvent temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
3. Ellingson BM, Laviolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM,. Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med 2011; 65: 1131-1143.
4. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okudo T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M,. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9: 53-60. (Pubitemid 29068231)
5. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM,. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010; 31: 538-548.
6. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: an early surrogate marker for therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029-2036. (Pubitemid 32045900)
7. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji S, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD,. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 2005; 102: 16759-16764. (Pubitemid 41688850)
8. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien CI, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck L, Rehemtulla A, Ross BD,. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102: 5524-5529. (Pubitemid 40530291)
9. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD,. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006; 8: 259-267.
10. Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien CI, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL,. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with convensional radiologic response and overall survival. J Clin Oncol 2008; 26: 3387-3394.
11. Ellingson BM, Malkin MG, Rand SD, Bedekar DP, Schmainda KM,. Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, Hawaii, USA, 2009. p 285.
12. Ellingson BM, Rand SD, Malkin MG, Schmainda KM,. Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol 2010; 97: 419-423.
13. Ellingson BM, Malkin MG, Rand SD, Hoyt A, Connelly J, Bedekar DP, Kurpad SN, Schmainda KM,. Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, Hawaii, USA, 2009. p 1010.
14. Reese TG, Heid O, Weisskoff RM, Wedeen VJ,. Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med 2003; 49: 177-182. (Pubitemid 36042349)
15. Cox RW, Jesmanowicz A,. Real-time 3D image registration for functional MRI. Magn Reson Med 1999; 42: 1014-1018.
16. Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien CI, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL,. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008; 26: 3387-3394.
17. Andersson JL, Smith SM, Jenkinson M,. FNIRT-FMRIB's non-linear image registration tool. Annual Meeting of the Organization Human Brain Mapping, Melborne, Australia; 2008.
18. Andersson JL, Jenkinson M, Smith SM,. Non-linear optimisation, FMRIB technical report TR07JA1; 2007.
19. Andersson JL, Jenkinson M, Smith SM,. Non-linear registration, aka spatial normalisation, FMRIB technical report TR07JA2; 2007.
20. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ,. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 1999; 18: 712-721. (Pubitemid 32262025)
21. Denton ER, Sonoda LI, Rueckert D, Rankin SC, Hayes C, Leach MO, Hill DL, Hawkes DJ,. Comparison and evaluation of rigid, affine, and nonrigid registration of breast MR images. J Comput Assist Tomogr 1999; 23: 800-805. (Pubitemid 29463825)
22. Ellingson BM, Malkin MG, Rand SD, Laviolette PS, Connelly JM, Mueller WM, Schmainda KM,. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 2011; 102: 95-103.
23. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280. (Pubitemid 20195640)
24. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF,. MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 2005; 26: 2466-2474.
25. Hoisak JD, Koh E-S, Yu E, Kassner A, Laperriere NJ, Menard C, Jaffray DA,. An image similarity-guided correspondence correction for voxel-wise analysis applied to MR imaging of glioblastoma multiforme acquired pre- and post-chemotherapy. In: Proceedings of the 18th Annual Meeting of ISMRM, Stockholm, Sweden, 2010. p 616.
26. Pope WB, Young JR, Ellingson BM,. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011; 11: 336-343.
27. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T,. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25: 4714-4721. (Pubitemid 350086472)
28. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK,. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009; 69: 5296-5300.
29. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy TF, Mischel PS, Lai A, Nghiemphu PL, Rahmanuddin S, Goldin J,. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252: 182-189.
30. Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV,. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 2009; 46: 786-802.